Literature DB >> 15908472

Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver.

Priyamvada Chandra1, Brendan M Johnson, Peijin Zhang, Gary M Pollack, Kim L R Brouwer.   

Abstract

This study examined the impact of hepatic transport protein modulation on the hepatobiliary disposition of a nonmetabolized probe substrate, 5- (and 6)-carboxy-2',7'dichlorofluorescein (CDF) in rat isolated perfused livers (IPLs). In vivo treatment with modulators (100 and 200 mg/kg/day clofibric acid, 80 mg/kg/day phenobarbital, and 25 mg/kg/day dexamethasone) was used to alter the expression of hepatic transport proteins [organic anion transporting polypeptide 1a1, multidrug resistance-associated protein (Mrp) 3, and Mrp2] governing the disposition of CDF. The basolateral and biliary excretion of CDF was measured in single-pass IPLs from control and treated rats. Modulators increased the percentage of CDF eliminated into perfusate of IPLs from treated rats ( approximately 20-35%) compared with controls ( approximately 10%); CDF biliary excretion was decreased in the treated groups. These observations are consistent with modulator-associated increases in the first-order rate constant governing CDF excretion from the hepatocytes into perfusate (k(perfusate)) or decreases in the first-order rate constant governing CDF excretion into bile (k(bile)). Pharmacokinetic modeling of the data and subsequent simulations revealed that the routes of CDF excretion were most sensitive to changes in k(perfusate). In contrast, hepatic accumulation of CDF was most sensitive to k(bile). The differential sensitivity of CDF excretory routes and hepatic accumulation to these rate constants is a function of intrahepatic distribution kinetics, which must be taken into consideration in assessing the potential impact of altered hepatobiliary transport processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908472     DOI: 10.1124/dmd.105.003665

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Authors:  James J Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2018-11-30       Impact factor: 3.922

2.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

3.  Novel Mechanisms of Valproate Hepatotoxicity: Impaired Mrp2 Trafficking and Hepatocyte Depolarization.

Authors:  Dong Fu; Panli Cardona; Henry Ho; Paul B Watkins; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2019-07-31       Impact factor: 4.849

4.  Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Authors:  Jacqueline Bezençon; James J Beaudoin; Katsuaki Ito; Dong Fu; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-06-03       Impact factor: 3.922

Review 5.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

6.  Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.

Authors:  Xianbin Tian; Brandon Swift; Maciej J Zamek-Gliszczynski; Martin G Belinsky; Gary D Kruh; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-02-14       Impact factor: 3.922

7.  Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells.

Authors:  Callie Drennen; Erin Gorse; Robert E Stratford
Journal:  J Pharm Sci       Date:  2017-12-14       Impact factor: 3.534

8.  Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.

Authors:  Nathan D Pfeifer; Arlene S Bridges; Brian C Ferslew; Rhiannon N Hardwick; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-30       Impact factor: 4.030

9.  Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR-) Rats.

Authors:  Jacqueline Bezençon; Chitra Saran; Janine Hussner; James J Beaudoin; Yueping Zhang; Hong Shen; John K Fallon; Philip C Smith; Henriette E Meyer Zu Schwabedissen; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2020-10-13       Impact factor: 3.534

Review 10.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Authors:  Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D Wang
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.